Accounting for costs, QALYs, and capacity constraints: Using discrete-event simulation to evaluate alternative service delivery and organizational scenarios for hospital-based glaucoma services

Medical Decision Making

Volumn 33, Issue 8, 2013, Pages 986-997

  Crane, Glenis J ^a   Kymes, Steven M ^b   Hiller, Janet E ^c   Casson, Robert ^a   Martin, Adam ^d   Karnon, Jonathan D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WASHINGTON UNIVERSITY   (United States)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

calibration; constrained resources; cost effectiveness; discrete event simulation; glaucoma, disease progression

Indexed keywords

CLINICAL PATHWAY; COST; DISEASE EXACERBATION; GLAUCOMA; HUMAN; PATHOPHYSIOLOGY; PUBLIC HOSPITAL; QUALITY ADJUSTED LIFE YEAR; SOUTH AUSTRALIA; THEORETICAL MODEL;

CALIBRATION; CONSTRAINED RESOURCES; COST-EFFECTIVENESS; DISCRETE-EVENT SIMULATION; GLAUCOMA, DISEASE PROGRESSION;

COSTS AND COST ANALYSIS; CRITICAL PATHWAYS; DISEASE PROGRESSION; GLAUCOMA; HOSPITALS, PUBLIC; HUMANS; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; SOUTH AUSTRALIA;

MLCS; MLOWN;

EID: 84886002840     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X13478195     Document Type: Article

References (40)

1. Cooper K, Davies R, Raftery J, Roderick P. Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease. J Oper Res Soc. 2007 ; 59 (9). 1173-81
2. Jahn B, Pfeiffer KP, Theurl E, Tarride J-E, Goerree R. Capacity constraints and cost-effectiveness: a discrete event simulation for drug-eluting stents. Med Decis Making. 2010 ; 30: 16-28
3. Karnon J, Caffrey O, Pham C, et al. Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: estimating the costs and consequences of variation in clinical practice.. 2012 ;:
4. Pham C, Caffrey O, Karnon J, Ben-Tovim DI, Hakendorf P, Crotty M. Evaluating the effects of variation in clinical practice: a risk adjusted cost-effectiveness (RAC-E) analysis of acute stroke services. BMC Health Serv Res. 2012 ; 12: 266
5. Stahl JE, Rattner D, Wiklund R, Lester J, Beinfeld M, Gazelle GS. Reorganizing the system of care surrounding laparoscopic surgery: a cost-effectiveness analysis using discrete-event simulation. Med Decis Making. 2004 ; 24 (5). 461-71
6. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manage Sci. 1998 ; 1 (2). 133-40
7. Cooper K, Davies R, Roderick P, Chase D, Raftery J. The development of a simulation model of the treatment of coronary heart disease. Health Care Manage Sci. 2002 ; 5 (4). 259-67
8. Casson RJ, Chidlow G, Wood JPM, Crowston JG, Goldberg I. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. In press ;:
9. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol. 2003 ; 48: S3-7
10. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 ; 120 (10). 1268-79
11. Gazzard G, Foster PJ, Devereux JG, et al. Intraocular pressure and visual field loss in primary angle closure and primary open angle glaucomas. Br J Ophthalmol. 2003 ; 87 (6). 720-5
12. Chen M-J, Cheng C-Y, Chou C-K, Liu CJL, Hsu W-M. The long-term effect of Nd:YAG laser iridotomy on intraocular pressure in Taiwanese eyes with primary angle-closure glaucoma. J Chin Med Assoc. 2008 ; 71 (6). 300-4
13. Folgar FA, de Moraes CGV, Prata TS, et al. glaucoma surgery decreases the rates of localized and global visual field progression. Am J Ophthalmol. 2010 ; 149 (2). 258-64.e2
14. Sherwood MB, Lattimer J, Hitchings RA. Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. Br J Ophthalmol. 1987 ; 71 (3). 188-91
15. Melbourne: East Melbourne Eye Research Australia ; 2004 :
16. Crane G, Karnon J, Kymes S, Casson R, Hiller J. Implementation and calibration of a constrained resource health outcomes simulation model of hospital-based glaucoma services.. 2012 ;:
17. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005 ; 21 (4). 337-48
18. Hamacher T, Schinzel M, Schölzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004 ; 88 (10). 1295-8
19. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994 ; 78 (12). 899-902
20. Yüksel N, AltIntaş Ö, Karabaş L, Alp B, Çaǧlar Y. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. Ophthalmologica. 1999 ; 213 (4). 228-33
21. Rahman MQ, Montgomery DMI, Lazaridou MN. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience. Br J Ophthalmol. 2009 ; 93 (12). 1572-5
22. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005 ; 140 (4). 598-606
23. Sydney, Australia: ; 2003: 1-92.
24. Rein DB, Wirth KE, Johnson CA, Lee PP. Estimating quality-adjusted life year losses associated with visual field deficits using methodological approaches. Ophthalmic Epidemiol. 2007 ; 14 (4). 258-64
25. Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2011 ; 29 (1). 35-49
26. Jay JL, Murray SB. Early trabeculectomy versus conventional management in primary open angle glaucoma. Br J Ophthalmol. 1988 ; 72 (12). 881-9
27. Rolim de, Moura C, Paranhos A, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev. 2007 ; (4). CD003919
28. Lee R, Hutnik CM. Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan. Can J Ophthalmol. 2006 ; 41 (4). 449-56
29. Wang JC, Chew PT. What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model. Clin Exp Ophthalmol. 2004 ; 32 (6). 578-83
30. Cantor LB, Katz LJ, Cheng JW, Chen E, Tong KB, Peabody JW. Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US. Curr Med Res Opin. 2008 ; 24 (10). 2905-18
31. Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012 ; 130 (4). 497-505
32. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011 ; 59: S93-6
33. Schertzer RM, Orton T, Pratt D. Practice patterns of Canadian glaucoma specialists: planning for the next generation. Can J Ophthalmol. 2007 ; 42 (4). 580-4
34. Altangerel U, Nallamshetty HS, Uhler T, et al. Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program. Can J Ophthalmol. 2009 ; 44 (1). 66-9
35. Vuori ML, Nikoskelainen E. Evaluation of glaucoma patients referred to a university clinic during one year. Acta Ophthalmol Scand. 1997 ; 75 (6). 692-4
36. Holtzer-Goor K, van Sprundel E, Lemij H, Plochg T, Klazinga N, Koopmanschap M. Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial. BMC Health Serv Res. 2010 ; 10 (1). 312
37. Banes MJ, Culham LE, Bunce C, Xing W, Viswanathan A, Garway-Heath D. Agreement between optometrists and ophthalmologists on clinical management decisions for patients with glaucoma. Br J Ophthalmol. 2006 ; 90 (5). 579-85
38. Gardiner SK, Crabb DP. Examination of different pointwise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci. 2002 ; 43: 1400-7
39. Siciliani L, Hurst J. Tackling excessive waiting times for elective surgery: a comparative analysis of policies in 12 OECD countries. Health Policy. 2005 ; 72 (2). 201-15
40. Patrick J, Puterman ML. Reducing wait times through operations research: optimizing the use of surge capacity. Health Policy. 2008 ; 3 (3). 75-88